New vaccine aims to stop lung cancer from coming back

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer and whose tumors are PD-L1 negative. The goal is to see if the vaccine can train the immune system to recognize and destroy any remaining cancer cells, preventing the cancer from returning. About 30 adults with no signs of cancer after surgery will receive the vaccine with or without N-803 over several months and be followed for up to 5 years.